NextCure reports Q3 2026 results as Avere merger financing grows to $820 million
Stockholders will vote December 9 on the deal after the SEC cleared NextCure's S-4, while cash fell to $8.7 million.
SEC filing
2 stories
Stockholders will vote December 9 on the deal after the SEC cleared NextCure's S-4, while cash fell to $8.7 million.
SEC filing
Dr. Udayan Guha's exit, effective October 31, 2026, comes as NextCure's merger with Avere Therapeutics remains pending.
SEC filing